Ardiden to release graphite assay results

|

Published 10-MAR-2017 16:21 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Lithium/graphite explorer, Ardiden (ASX:ADV) has advised the market that its drilling program at the Manitouwadge graphite project located in Ontario, Canada has been completed and assay results are imminent.

Given positive visual results from the last 19 drill holes in the 30 hold drill program indicated that the holes continued to intersect multiple layers of large flake graphitic mineralisation over various widths, the assay results are keenly anticipated.

On this note management said, “Visual logging and inspections of the diamond drill core by Ardiden’s geological team have identified multiple layers of thick graphitic mineralisation in zones up to 65.4 metres in true width”.

Importantly, the mineralisation intersected in the current diamond drilling program has verified the interpreted extensions of the graphitic mineralisation zones for a strike extension of over 700 metres as highlighted below.

Second phase drilling at Seymour Lake about to commence

There has been some strong news flow from ADV with the completion of first phase drilling at the Seymour Lake lithium project, also located in Ontario, confirming the presence of high grade lithium mineralisation at surface and at depth at the North Aubry prospect. Assay results from the Central Aubry prospect also confirmed high-quality spodumene mineralisation.

ADV is looking to expand the initial maiden lithium resource potential at North Aubry to ensure there will be sufficient resources to be economically viable for any potential future mining operations.

It should be noted here that Ardiden is an early stage play and investors considering this stock for their portfolio should seek professional financial advice.

Geological interpretation from first phase drilling indicates that mineralisation at the North Aubry prospect appears to be plunging to the north-west, which could be indicating a possible deep pegmatite feeder zone along the western controlling structure as illustrated below.

Management said preparations are almost complete to commence Phase 2 of the diamond drilling program at Seymour Lake, which will be designed to further test the extensions of the lithium mineralisation zones on the western and northern aspects of the North Aubry prospect, as well as drill testing the possible pegmatite feeder zone on the western flank.

One of the key focuses in terms of analysing data will be testing the concept of possible dilation along the feeder zone, which may strike south towards the central Aubry prospect, which could explain some of the similarities between the two prospect areas.

Highlighting the significance of such a development, management said, “If this geological interpretation is found to be accurate it could dramatically expand the potential size of the lithium mineralisation zones and therefore increase the scale of the lithium deposit.”

tags

LITHIUM


General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X